白血病CD20、CD33、CD45及MDR表达和靶抗原筛选  

Expression of CD20,CD33,CD45,MDR and selection of targeted antigen in leukemia patients.

作　　者：刘捷[1] 张王刚[1] 柏春梅[1] 陈银霞[1] 曹星梅[1] 田玮[1] 

机构地区：[1]西安交通大学第二医院血液内科,陕西西安710004

出　　处：《现代肿瘤医学》2006年第1期86-88,共3页Journal of Modern Oncology

摘　　要：目的观察白血病患者CD20、CD33、CD45及MDR表达及抗原强度的变化,筛选特异的靶抗原,探讨抗体靶向治疗的应用价值。方法应用间接免疫荧光法检测白血病细胞CD20、CD33、CD45及MDR表达和抗原强度变化。结果CD20、CD33、MDR阳性率分别为38.1%、81.5%、13.3%;髓性白血病中CD33抗原表达比CD45强,差异有显著性(P<0.05);CD33与MDR表达,差异无显著性。CD20与CD45、MDR在淋巴细胞白血病细胞上表达,差异无显著性。结论CD33特异性强,抗原性强,适合作靶抗原,MDR也是耐药白血病治疗的较好靶抗原。抗体靶向治疗将是白血病治疗的一条新途径。Objective To detect the expression and intensity variety of CD20, CD33 ,CD45,MDR on surface of leukemia cells ,investigate the clinical value of specific targeted antigen in antibody targeted therapy. Methods Using indirect immunofluorescence method, the positive rates and antigen intensity variety of CD20,CD35, CD45 and MDR were detected in 75 leukemia patients. Results The positive rates of CD20,CD33,MDR were 38.1% ,81.5% , 13.3% , respectively. The expression of CD33 was specific and high in AML patients. The difference was significant. Conclusion CD33 was an optimum targeted antigen. MDR was a targeted antigen in drug resistance AL. Antibody - targeted therapy will be a new way in treatment of leukemia.

关 键 词：白血病 MDR 抗体靶向治疗 

分 类 号：R733.7[医药卫生—肿瘤]